For decades, the blood-brain barrier has been the single greatest pharmacological obstacle in neurology — a fortress that keeps most therapeutic molecules from reaching their target. Emerging ultrasound-based technologies are now offering a non-invasive, reversible key to that fortress, with implications for millions living with Alzheimer's disease, Parkinson's disease, and malignant brain tumors.
This comprehensive review in Biomaterials Advances consolidates the mechanistic and clinical landscape of focused ultrasound (FUS) as a drug-delivery platform for the central nervous system. The core mechanism relies on acoustic cavitation: microbubbles (MBs) injected systemically oscillate under FUS exposure, creating transient mechanical forces that temporarily loosen tight junction proteins in BBB endothelial cells, allowing co-administered therapeutics to penetrate brain parenchyma within a spatially defined zone. The review systematically examines three delivery architectures — MB-assisted, standalone nanoparticle-based, and hybrid MB-nanoparticle composite systems — each offering distinct trade-offs in payload capacity, targeting precision, and safety profiles. Particular attention is given to FUS-MB applications in Alzheimer's, Parkinson's, and glioma, where early-phase human trials are beginning to define therapeutic windows. The authors also flag sonodynamic therapy and magnetically guided nanorobots as frontier extensions of the platform.
Placing this review in context, FUS-mediated BBB opening has accelerated rapidly since foundational animal work in the early 2000s demonstrated reversible, safe opening without gross tissue damage. Human feasibility studies — including work at institutions such as Columbia and Sunnybrook — have since confirmed transient, MRI-guided BBB disruption is achievable in patients. What remains incompletely resolved are the long-term safety profile of repeated BBB openings, optimal acoustic parameters across heterogeneous patient populations, and whether enhanced drug penetration translates to measurable clinical benefit at scale. This review is an incremental but well-organized synthesis rather than a paradigm-shifting finding; its primary value is as a translational roadmap for researchers bridging the gap between preclinical promise and clinical reality in one of medicine's most refractory therapeutic domains.